New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?
- PMID: 35686738
- DOI: 10.1002/pbc.29805
New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?
Comment on
-
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.Pediatr Blood Cancer. 2022 Aug;69(8):e29716. doi: 10.1002/pbc.29716. Epub 2022 Apr 21. Pediatr Blood Cancer. 2022. PMID: 35451176
References
REFERENCES
-
- Therrell BL Jr, Lloyd-Puryear MA, Eckman JR, Mann MY. Semin Perinatol. 2015;39:238-251. https://doi.org/10.1053/j.semperi.2015.03.008
-
- Estepp JH, Kalpatthi R, Woods G, et al. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease, age 4 to 11 years. Pediatr Blood Cancer. 2022;21:e29716. https://doi.org/10.1002/pbc.29716
-
- Hebbel RP, Hedlund BE. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am J Hematol. 2018;93:321-325. https://doi.org/10.1002/ajh.24975
-
- Henry ER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021;138:1172-1181. https://doi.org/10.1182/blood.2021012070
-
- Quinn CT, Ware RE. Increased oxygen affinity: to have and to hold. Blood. 2021;138:1094-1095. https://doi.org/10.1182/blood.2021013242
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical